Obesity

Eli Lilly's triple agonist achieved 28.3% weight loss at 80 weeks and 30.3% at 104 weeks, matching bariatric surgery levels.

Most surveyed individuals with obesity support lower-cost options for weight maintenance, which would allow better coverage for injectable incretin mimetics for weight management during active weight loss.

Fatima Cody Stanford, MD, MPH, MPA, exposes obesity health disparities, GLP-1 access hurdles, payer policy fixes, and how stigma in care blocks equitable treatment.

Fatima Cody Stanford, MD, MPH, MPA, breaks down the brain mechanisms behind obesity and how to empower patients and improve clinical outcomes.

The results show that semaglutide could be a novel treatment for patients with alcohol use disorder moving forward.

Tim Church, MD, PhD, MPH, explains that access to care—not willpower—is the central barrier to GLP-1 use, and says employer coverage decisions are finally catching up.

A 2026 survey finds 2 in 3 employed adults would be more likely to use GLP-1 weight-loss drugs if employer coverage or behavioral support programs were available.

This retrospective analysis examines employees with obesity and reports on glucagon-like peptide-1 receptor agonist use, comorbidities, and work outcomes over time.

FDA approves Eli Lilly's orforglipron (Foundayo), the first GLP-1 obesity pill with no food or water restrictions.

Novo Nordisk launches a Wegovy subscription program to reduce costs, expand access, and improve long-term adherence.

Analysis of billing codes before and after implementation of a care process for weight-focused visits revealed increased primary care revenue for these encounters.

Obesity enlarges organs, adding cells that raise liver, kidney, and pancreatic cancer risk, such that organ size may predict danger better than body mass index.

"The One Hundred Year Effect," a documentary about retired Oregon Health and Science Professor Kent Thornburg, PhD, and his efforts to spread the message of the harms of chronic disease, recently premiered.

The FDA approved higher-dose semaglutide 7.2 mg (Wegovy HD), marking the fourth drug approved under the Commissioner's National Priority Voucher pilot program.

The Go for Bold initiative, which aims to help individuals in Washington County, Maryland, lose 1 million lb by 2030, serves as a successful, replicable model for community-wide health improvement.

In a cohort of US veterans, there were reduced risks of adverse clinical outcomes in people with SUDs and of developing an SUD in those taking GLP-1s.

FDA approves 4-dose KwikPen for tirzepatide (Zepbound; Eli Lilly), offering a full month of weight management treatment in 1 device.

Oral Wegovy reshapes GLP-1 costs: cash pay can be cheaper, insurance pricing often matches shots, and coverage hinges on employer benefits and coding.

Individuals can use these 5 ways to minimize their cancer risk during National Cancer Prevention Month and beyond.

To protect patients, the FDA will restrict ingredients in unapproved compounded GLP‑1 drugs and crack down on misleading marketing.

Oral semaglutide (Wegovy; Novo Nordisk) expands GLP-1 weight-loss options, but pharmacy budgets and health care cost pressures persist.

Obesity market overview for employers: data on GLP-1s for obesity, digital solutions, and benefit strategies to control costs and outcomes.

Adults who are underweight, overweight, or obese face higher medical expenditures, varying by age, sex, and care setting.

Explore the evolving GLP-1 landscape with insights from industry experts, shaping future health strategies and plan designs for employers.

Nimbus Therapeutics and Eli Lilly announce their partnership to develop a novel oral drug for patients with obesity and other metabolic disorders.